Roflumilast Patent Expiration
Roflumilast is Used for reducing the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. It was first introduced by Astrazeneca Pharmaceuticals Lp
Roflumilast Patents
Given below is the list of patents protecting Roflumilast, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zoryve | US11707454 | Topical roflumilast formulation having antifungal properties | Dec 03, 2041 | Arcutis |
| Zoryve | US11129818 | Topical roflumilast formulation having improved delivery and plasma half life | Aug 25, 2037 | Arcutis |
| Zoryve | US10940142 | Inhibition of crystal growth of roflumilast | Jun 07, 2037 | Arcutis |
| Zoryve | US11793796 | Inhibition of crystal growth of roflumilast | Jun 07, 2037 | Arcutis |
| Zoryve | US11819496 | Topical roflumilast formulation having improved delivery and plasma half-life | Jun 07, 2037 | Arcutis |
| Zoryve | US11992480 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | Jun 07, 2037 | Arcutis |
| Zoryve | US12005051 | Topical roflumilast formulation having improved delivery and plasma half life | Jun 07, 2037 | Arcutis |
| Zoryve | US12005052 | Topical roflumilast formulation having improved delivery and plasma half-life | Jun 07, 2037 | Arcutis |
| Zoryve | US12011437 | Roflumilast formulations with an improved pharmacokinetic profile | Jun 07, 2037 | Arcutis |
| Zoryve | US12016848 | Roflumilast formulations with an improved pharmacokinetic profile | Jun 07, 2037 | Arcutis |
| Zoryve | US12042487 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | Jun 07, 2037 | Arcutis |
| Zoryve | US12220409 | Roflumilast formulations with an improved pharmacokinetic profile | Jun 07, 2037 | Arcutis |
| Zoryve | US12257242 | Inhibition of crystal growth of roflumilast | Jun 07, 2037 | Arcutis |
| Zoryve | US12310956 | Topical roflumilast formulation having improved delivery and plasma half-life | Jun 07, 2037 | Arcutis |
| Zoryve | US9884050 | Inhibition of crystal growth of roflumilast | Jun 07, 2037 | Arcutis |
| Zoryve | US9907788 | Inhibition of crystal growth of roflumilast | Jun 07, 2037 | Arcutis |
| Daliresp | US8536206 | Process for the preparation of roflumilast |
Mar 08, 2024
(Expired) | Astrazeneca |
| Daliresp | US8604064 | Process for the preparation of roflumilast |
Mar 08, 2024
(Expired) | Astrazeneca |
| Daliresp | US8618142 | Process for the preparation of roflumilast |
Mar 08, 2024
(Expired) | Astrazeneca |
| Daliresp | US8431154 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb 19, 2023
(Expired) | Astrazeneca |
| Daliresp | US9468598 | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb 19, 2023
(Expired) | Astrazeneca |
| Daliresp | US5712298 | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan 27, 2020
(Expired) | Astrazeneca |
| Daliresp | US5712298 | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan 27, 2015
(Expired) | Astrazeneca |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Roflumilast's patents.
Latest Legal Activities on Roflumilast's Patents
Given below is the list recent legal activities going on the following patents of Roflumilast.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Electronic Review Critical
| 07 Jun, 2024 | US9884050 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 May, 2024 | US10940142 |
| Mail O.P. Petition Decision | 11 Mar, 2024 | US9884050 |
| Email Notification Critical
| 11 Mar, 2024 | US9884050 |
| Mail-Petition Decision - Dismissed Critical
| 07 Mar, 2024 | US9884050 |
| Petition Decision - Dismissed Critical
| 06 Mar, 2024 | US9884050 |
| O.P. Petition Decision | 05 Mar, 2024 | US9884050 |
| Mail O.P. Petition Decision | 12 Feb, 2024 | US11819496 |
| Email Notification Critical
| 12 Feb, 2024 | US11819496 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 08 Feb, 2024 | US11819496 |
Roflumilast's Family Patents
